Investing in Innovation Africa (i3), a pan-African accelerator backed by the Bill & Melinda Gates Foundation and other major global health players, has announced a significant shift in its strategy for its third cohort of healthtech startups. The accelerator will now focus on supporting 5–7 growth-stage companies specializing in pharmacy care innovations, a move prompted by the U.S. State Department’s recent “stop-work” directive on foreign aid.

The directive, issued on January 25, 2025, has raised concerns about disruptions to the distribution of essential medicines across Africa’s healthcare supply chains. In response, i3 is prioritizing startups that can rapidly scale solutions to address immediate gaps in patient care. The initiative aims to foster locally driven, market-creating approaches to health product distribution and service delivery, reducing reliance on external aid.

Originally designed to support up to 15 startups, including early-stage ventures, i3’s third cohort will now concentrate on companies with proven traction and the potential to scale quickly. Selected startups will receive up to $225,000 in grant funding, along with access to partnerships and technical support to expand their reach.

The initiative is funded by a coalition of global health leaders, including the Gates Foundation, MSD, Cencora, the Endless Foundation, HELP Logistics, Sanofi’s Global Health Unit, and Chemonics International. These partners have reaffirmed their commitment to i3’s mission, despite the challenges posed by the U.S. aid freeze.

Applications for the third cohort are open until February 28, with selected startups to be announced on April 30. A virtual Q&A session will be held on February 21 to address questions about the application process.

The U.S. State Department’s “stop-work” directive, part of a broader freeze on foreign aid initiated by the Trump administration, has sent shockwaves through global health initiatives. Africa, which relies heavily on international aid for healthcare infrastructure and medicine distribution, is particularly vulnerable to such disruptions.

i3’s pivot reflects a growing recognition of the need for self-reliant, market-driven solutions in Africa’s healthcare sector. By supporting growth-stage startups, the accelerator aims to strengthen local supply chains and reduce dependency on external funding.

While i3’s immediate focus is on growth-stage companies, the accelerator plans to expand its support to early-stage startups in the future. For now, the initiative is channeling its resources into ventures that can deliver tangible results in the short term, particularly in the pharmacy care sector.

The selected startups will join a network of innovators working to transform healthcare delivery across Africa. Previous i3 cohorts have included companies leveraging technology to improve medicine distribution, enhance supply chain efficiency, and expand access to primary care.

As the global health landscape continues to evolve, accelerator programs like i3 are playing a critical role in fostering resilience and innovation in Africa’s healthcare systems. By prioritizing locally driven solutions, i3 is not only addressing immediate challenges but also laying the groundwork for a more sustainable future.

Key Details:

• Application Deadline: February 28, 2025
• Cohort Announcement: April 30, 2025
• Virtual Q&A Session: February 21, 2025
• Apply Here: innovationsinafrica.com/application